155 results on '"Levi, Shai"'
Search Results
2. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
3. The impact of a Facebook campaign among mothers on HPV vaccine uptake among their daughters: A randomized field study
4. Effect of Stock Liquidity on the Firm's Investment and Production.
5. Cell-to-cell bacterial interactions promoted by drier conditions on soil surfaces
6. The Differential Informativeness of Positive and Negative Stock Returns.
7. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study
8. P942: MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY
9. P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL
10. P571: OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS
11. P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.
12. The Impact of Investment Priming on Donations to Social Causes: Evidence from Two Field Experiments
13. Epidemiology of oral, salivary gland and pharyngeal cancer in children and adolescents between 1970 and 2011
14. Do firms underreport information on cyber-attacks? Evidence from capital markets
15. Managerial incentives, options, and cost-structure choices
16. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA .5 subvariant surge
17. The Impact of Social Investing on Charitable Donations
18. Margin Forecasts by Managers and Analysts
19. Asymmetric decrease in liquidity trading before earnings announcements and the announcement return premium
20. Do Temporary Increases in Information Asymmetry Affect the Cost of Equity?
21. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study
22. The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
23. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
24. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
25. The Effect of Stock Liquidity on the Firm’s Investment and Production
26. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
27. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
28. Business Corruption and Economic Prosperity.
29. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.
30. Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study
31. The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective
32. sj-docx-1-tah-10.1177_20406207211035272 – Supplemental material for Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study
33. Outcomes of Acute Myeloid Leukemia Patients Suffering from an Additional Active Malignancy Treated with Venetoclax and Azacitidine: A Single Center Experience
34. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
35. Does fiduciary duty to creditors reduce debt covenant violation avoidance behavior?
36. Voluntary disclosure of accruals in earnings press releases and the pricing of accruals
37. The Impact of Social Investing on Charitable Donations
38. Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study
39. Stability of neutral delay differential equations with applications in a model of human balancing
40. Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review
41. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma
42. Random Forest Algorithm Improves Detection of Physiological Activity Embedded within Reflectance Spectra Using Stomatal Conductance as a Test Case
43. The Differential Informativeness of Positive and Negative Stock Returns
44. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
45. Strategic Trading at the Preopening after Earnings Announcements
46. Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study
47. Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg
48. Treatment Patterns and Clinical Outcomes Across Consecutive Treatment Lines in Multiple Myeloma Patients: Single-Center Real World Experience.
49. Insider Trading and Disclosure: The Case of Cyberattacks
50. Stability of third order neutral delay differential equations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.